- Home
- HCWB vs FENG Comparison
HCWB vs FENG Comparison
Compare HCWB & FENG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCWB
- FENG
- Stock Information
- Founded
- HCWB 2018
- FENG 1998
- Country
- HCWB United States
- FENG China
- Employees
- HCWB N/A
- FENG N/A
- Industry
- HCWB Biotechnology: Pharmaceutical Preparations
- FENG Broadcasting
- Sector
- HCWB Health Care
- FENG Industrials
- Exchange
- HCWB Nasdaq
- FENG Nasdaq
- Market Cap
- HCWB 26.6M
- FENG 29.7M
- IPO Year
- HCWB 2021
- FENG 2011
- Fundamental
- Price
- HCWB $0.37
- FENG $2.49
- Analyst Decision
- HCWB
- FENG
- Analyst Count
- HCWB 0
- FENG 0
- Target Price
- HCWB N/A
- FENG N/A
- AVG Volume (30 Days)
- HCWB 274.4K
- FENG 3.6K
- Earning Date
- HCWB 11-14-2024
- FENG 03-11-2025
- Dividend Yield
- HCWB N/A
- FENG N/A
- EPS Growth
- HCWB N/A
- FENG N/A
- EPS
- HCWB N/A
- FENG N/A
- Revenue
- HCWB $3,495,990.00
- FENG $99,426,474.00
- Revenue This Year
- HCWB $229.19
- FENG N/A
- Revenue Next Year
- HCWB N/A
- FENG N/A
- P/E Ratio
- HCWB N/A
- FENG N/A
- Revenue Growth
- HCWB 22.27
- FENG N/A
- 52 Week Low
- HCWB $0.28
- FENG $1.20
- 52 Week High
- HCWB $2.52
- FENG $4.15
- Technical
- Relative Strength Index (RSI)
- HCWB 43.55
- FENG 51.73
- Support Level
- HCWB $0.33
- FENG $2.31
- Resistance Level
- HCWB $0.38
- FENG $2.65
- Average True Range (ATR)
- HCWB 0.05
- FENG 0.11
- MACD
- HCWB -0.00
- FENG 0.01
- Stochastic Oscillator
- HCWB 25.97
- FENG 54.29
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
About FENG Phoenix New Media Limited
Phoenix New Media Ltd is a media company providing premium content on an integrated platform across the internet, mobile and TV channels in China. The company organizes its operations into two main segments: Net advertising services and Paid services. It provides its content and services through three channels: ifeng.com channel, video channel, and mobile channel. The company also offers a wide range of paid services including mobile value-added services, games, and content sales. It generates the majority of its revenue from Net advertising services. Geographically, it derives revenue from China.